AVLN Avalyn Pharma Inc.
Avalyn Pharma Inc. (AVLN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 28% planned / 72% discretionary
Largest single sale: $5.0M.
Where they traded
Last open-market purchase: May 1, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Baranowski Lyn 2 fills | Chief Executive Officer | Sell 10b5-1 | 7,200 | $27.95 | $201.3K | 735 −90.7% of holding | |
| Baranowski Lyn 3 fills | Chief Executive Officer | Sell 10b5-1 | 45,300 | $27.82 | $1.3M | 5,700 −88.8% of holding | |
| Carlson Douglas R 3 fills | See Remarks | Sell 10b5-1 | 14,875 | $27.90 | $415.0K | 3,348 −81.6% of holding | |
| Rhodes Melissa 3 fills | Chief Operating Officer | Sell 10b5-1 | 13,300 | $27.90 | $371.0K | 2,425 −84.6% of holding | |
| Lazarus Howard 3 fills | Chief Medical Officer | Sell 10b5-1 | 13,300 | $27.90 | $371.0K | 2,277 −85.4% of holding | |
| FMR LLC 2 fills | 10% Owner | Sell | 53,454 | $30.21 | $1.6M | 2,103,970 −2.5% of holding | |
| FMR LLC 2 fills | 10% Owner | Sell | 175,000 | $29.07 | $5.1M | 2,110,874 −7.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.